Good vaccine news has been pouring in today — this afternoon it was the turn of the Janssen vaccine, made by US company Johnson & Johnson. An international trial, in which the vaccine was tested against various strains of the virus, has found the jab to have 66 per cent overall efficacy.
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in